Generation Bio Co. financial data

Symbol
GBIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
301 Binney Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 675 % -33.4%
Debt-to-equity 135 % +110%
Return On Equity -120 % -130%
Return On Assets -51.1 % -60.6%
Operating Margin -716 % +69.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67M shares +0.8%
Common Stock, Shares, Outstanding 67M shares +1.16%
Entity Public Float 155M USD -48.2%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 66.6M shares +3.32%
Weighted Average Number of Shares Outstanding, Diluted 66.6M shares +3.32%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 19.9M USD +237%
Research and Development Expense 61.3M USD -34.5%
General and Administrative Expense 37.8M USD -25.7%
Operating Income (Loss) -142M USD -2.76%
Nonoperating Income (Expense) 10.7M USD -10.3%
Net Income (Loss) Attributable to Parent -132M USD -3.99%
Earnings Per Share, Basic -1.98 USD/shares -1.02%
Earnings Per Share, Diluted -1.98 USD/shares -1.02%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76.3M USD +14.8%
Marketable Securities, Current 109M USD -45%
Accounts Receivable, after Allowance for Credit Loss, Current 1.22M USD
Other Assets, Current 160K USD -44.8%
Assets, Current 193M USD -29.2%
Property, Plant and Equipment, Net 15.3M USD -40.7%
Operating Lease, Right-of-Use Asset 20.3M USD -70.9%
Other Assets, Noncurrent 539K USD -22.8%
Assets 231M USD -38.3%
Accounts Payable, Current 1.41M USD -40%
Employee-related Liabilities, Current 5.98M USD -54.8%
Contract with Customer, Liability, Current 5.68M USD
Liabilities, Current 35.1M USD -12.2%
Contract with Customer, Liability, Noncurrent 55.1M USD
Operating Lease, Liability, Noncurrent 80.6M USD -10.3%
Other Liabilities, Noncurrent 223K USD
Liabilities 145M USD -15.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 159K USD -42%
Retained Earnings (Accumulated Deficit) -703M USD -23%
Stockholders' Equity Attributable to Parent 86.2M USD -57.6%
Liabilities and Equity 231M USD -38.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.7M USD -14.5%
Net Cash Provided by (Used in) Financing Activities -125K USD -100%
Net Cash Provided by (Used in) Investing Activities -553K USD +90.2%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 67M shares +1.16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 78.5M USD +8.61%
Deferred Tax Assets, Valuation Allowance 214M USD +22.1%
Operating Lease, Liability 62M USD
Payments to Acquire Property, Plant, and Equipment 1.92M USD +154%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -132M USD -4.38%
Lessee, Operating Lease, Liability, to be Paid 137M USD +31.1%
Property, Plant and Equipment, Gross 38.2M USD -16%
Operating Lease, Liability, Current 13M USD +60.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15.6M USD +2.83%
Lessee, Operating Lease, Liability, to be Paid, Year One 15.2M USD +13.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 38.9M USD -13.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 16.1M USD +2.92%
Deferred Tax Assets, Operating Loss Carryforwards 105M USD +8.37%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 16.6M USD +2.83%
Operating Lease, Payments 1.9M USD -38.7%
Additional Paid in Capital 789M USD +1.92%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4.93M USD -6.31%
Deferred Tax Assets, Net of Valuation Allowance 222M USD +12.4%
Share-based Payment Arrangement, Expense 14.6M USD -40%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%